AMENDMENTS TO THE CLAIMS:

This listing of claims replaces all prior versions and listings of claims in the application:

1-138 (Cancelled).

139. (New) An isolated or recombinant polypeptide comprising a polypeptide sequence that has at least 96% sequence identity to a polypeptide sequence comprising amino acid residues 81-265 of SEQ ID NO:4, wherein said isolated or recombinant polypeptide has an ability to induce an immune response against human epithelial cell adhesion molecule (EpCAM) or an antigenic fragment of human EpCAM.

140. (New) The polypeptide of claim 139, wherein the polypeptide comprises a polypeptide sequence that has at least about 96% sequence identity to a polypeptide sequence comprising amino acid residues 24-265 of SEQ ID NO:4.

141. (New) The polypeptide of claim 139, wherein the polypeptide comprises a polypeptide sequence that has at least about 96% sequence identity to the polypeptide sequence of SEQ ID NO:4.

142. (New) The polypeptide of claim 139, wherein the polypeptide comprises amino acid residues 81-265 of SEQ ID NO:4.

143. (New) The polypeptide of claim 140, wherein the polypeptide comprises amino acid residues 24-265 of SEQ ID NO:4.

144. (New) The polypeptide of claim 141, wherein the polypeptide comprises the polypeptide sequence of SEQ ID NO:4.

145. (New) The polypeptide of claim 139, wherein the polypeptide has an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof.

146. (New) The polypeptide of claim 139, wherein the polypeptide induces a T cell response against human EpCAM.

147. (New) The polypeptide of claim 146, wherein the polypeptide T cell proliferation response against human EpCAM.

148. (New) The polypeptide of claim 139, wherein the polypeptide induces production of at least one cytokine.

149. (New) The polypeptide of claim 139, wherein the at least one cytokine is interferon-gamma.

150. (New) The polypeptide of claim 139, wherein the polypeptide is glycosylated and/or pegylated.

151. (New) The polypeptide of claim 139, wherein the immune response comprises the production of antibodies that bind human EpCAM, proliferation of T cells, and production or one or more cytokines.

152. (New) The polypeptide of claim 140, wherein the polypeptide has an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof.

153. (New) The polypeptide of claim 140, wherein the polypeptide induces a T cell response against human EpCAM.

154. (New) The polypeptide of claim 140, wherein the polypeptide induces production of at least one cytokine.

155. (New) The polypeptide of claim 140, wherein the immune response comprises the production of antibodies that bind human EpCAM, proliferation of T cells, and production or one or more cytokines.

156. (New) The polypeptide of claim 141, wherein the immune response comprises at least one of an ability to induce production of antibodies against human EpCAM or an antigenic fragment thereof, induce a T cell response against human EpCAM, or induce production of at least one cytokine.

157. (New) A composition comprising the polypeptide of claim 139 and a carrier, diluent, or excipient.

158. (New) The composition of claim 157, wherein the composition further comprises at least one adjuvant, immunomodulatory polypeptide, or cytokine, or any combination thereof.